血清tRNA衍生片段tRF-17-79MP9PP的表达及与乳腺癌患者预后的相关性

Correlation between the expression level of serum tRNA derived fragment tRF⁃17⁃79MP9PP and the prognosis of breast cancer patients

目的检测乳腺癌患者血清tRNA衍生物tRF-17-79MP9PP(tRF-17)的表达水平,并分析其与患者预后的相关性。方法选取2016年6月至2019年12月本院收治并确诊的70例乳腺癌患者及25例健康人对照组的血清标本,记录患者的临床资料和数据。采用实时荧光定量PCR(qRT-PCR)检测两组血清tRF-17的表达水平;绘制ROC曲线并分析tRF-17对乳腺癌的临床筛查价值;采用Spearman相关分析tRF-17与血液炎症指标以及肿瘤标志物的相关性,随访截止日期为2023年4月,使用单因素和多因素COX回归分析乳腺癌预后不良的影响因素。结果与健康人对照组的14.09(5.14,21.34)相比,乳腺癌患者血清tRF-17的表达水平[3.99(0.70,10.46)]显著降低,差异有统计学意义(Z=-3.575,P<0.01);其筛查乳腺癌的ROC曲线下面积(AUCROC)为0.742(95%CI:0.635~0.849,P<0.01)。tRF-17高表达组乳腺癌患者的平均生存时间显著高于低表达组(75.97个月vs 56.06个月,log-rank P<0.01)。COX比例风险模型分析提示,淋巴结转移和血清tRF-17表达水平均是影响患者预后的独立危险因素(HR=1.723,95%CI:1.084~2.739,P<0.05;HR=0.189,95%CI:0.041~0.862,P<0.05)。结论乳腺癌患者血清tRF-17呈低表达,其表达水平是影响乳腺癌患者预后的独立危险因素,或可成为一种评估患者预后的生物学标志物。

Objective To investigate the expression level of serum tRNA derived tRF-17-79MP9PP(tRF-17)in patients with breast cancer and evaluate its correlation with the prognostic of the patients.Methods The serum samples were collected from 70 patients with breast cancer admitted to Jiangsu Cancer Hospital during June 2016 and December 2019 and 25 age-matched healthy women,and the clinical data of the patients were recorded.The expression level of serum tRF-17 was detected by real-time fluorescence quantitative PCR(qRT-PCR).The receiver operating characteristics(ROC)curve was used to evaluate the diagnosis value of tRF-17 in breast cancer patients.The correlations of tRF-17 with blood inflammatory indicators and tumor markers were analyzed by Spearman correlation analysis.The deadline for follow-up was April 2023.The factors influencing the prognosis of breast cancer were analyzed by the univari-ate and multivariate COX regression analysis.Results The expression levels of serum tRF-17 in breast cancer patients(3.99[0.70,10.46])were significantly lower than that in healthy controls(14.09[5.14,21.34],Z=-3.575,P<0.01).The area under the ROC curve of tRF-17 for diagnosing breast cancer was 0.742(95%CI:0.635-0.849,P<0.01).The average survival time of patients with high expression of tRF-17 was significantly higher than that of patients with low expression(75.97 months vs 56.06 months,log-rank P<0.01).The COX proportional hazards model analysis showed that lymph node metastasis and the expression level of serum tRF-17 were independent risk factors affecting the prognosis of the patients(HR=1.723,95%CI:1.084-2.739,P<0.05;HR=0.189,95%CI:0.041-0.862,P<0.05).Conclusion Serum tRF-17 is low expressed in breast cancer patients,and its expression level is an inde-pendent risk factor affecting the prognosis of breast cancer patients,which may be used as a biomarker to evaluate the prognosis of the patients.